Suppliers and packagers for generic pharmaceutical drug: AZITHROMYCIN

AZITHROMYCIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	AZITHROMYCIN	azithromycin	FOR SUSPENSION;ORAL	209201	ANDA	Aurobindo Pharma Limited	59651-007-15	1 BOTTLE in 1 CARTON (59651-007-15) / 15 mL in 1 BOTTLE	2018-10-09
Aurobindo Pharma Ltd	AZITHROMYCIN	azithromycin	FOR SUSPENSION;ORAL	209201	ANDA	Aurobindo Pharma Limited	59651-008-15	1 BOTTLE in 1 CARTON (59651-008-15) / 15 mL in 1 BOTTLE	2018-10-09
Aurobindo Pharma Ltd	AZITHROMYCIN	azithromycin	FOR SUSPENSION;ORAL	209201	ANDA	Aurobindo Pharma Limited	59651-008-23	1 BOTTLE in 1 CARTON (59651-008-23) / 22.5 mL in 1 BOTTLE	2018-10-09

AZITHROMYCIN API MANUFACTURING LANDSCAPE

Last updated: February 19, 2026

This report analyzes the global supplier base for Azithromycin Active Pharmaceutical Ingredient (API), focusing on key manufacturers, production capacities, regulatory compliance, and market dynamics. The analysis is critical for understanding supply chain resilience, cost drivers, and potential investment opportunities in the Azithromycin market.

WHO ARE THE PRIMARY AZITHROMYCIN API MANUFACTURERS GLOBALLY?

The production of Azithromycin API is concentrated among a relatively small number of manufacturers, with a significant portion of global supply originating from India and China. These manufacturers are characterized by their adherence to strict quality control standards and regulatory requirements necessary for pharmaceutical ingredient production.

Key Azithromycin API Manufacturers include:

• India-based Manufacturers:

  • Aarti Drugs Ltd.: A prominent Indian pharmaceutical company with significant API manufacturing capabilities. Aarti Drugs has established production lines for Azithromycin, serving both domestic and international markets. Their facilities are Good Manufacturing Practice (GMP) certified.
  • Divi's Laboratories Ltd.: A major global producer of APIs and intermediates. Divi's Laboratories is known for its large-scale production and cost-efficiency. They are a significant supplier of Azithromycin API, with extensive regulatory filings and approvals.
  • Laurus Labs Ltd.: A research-driven pharmaceutical company specializing in APIs. Laurus Labs has a strong focus on backward integration and process innovation for key products, including Azithromycin. Their manufacturing sites undergo regular inspections by international regulatory bodies.
  • Natco Pharma Ltd.: A vertically integrated pharmaceutical company with a strong presence in generics and complex APIs. Natco Pharma manufactures Azithromycin API, focusing on quality and compliance with stringent regulatory standards.
  • Granules India Ltd.: A leading global pharmaceutical company with a strong focus on API and finished dosage forms. Granules India has a substantial presence in the Azithromycin market, with multiple GMP-certified manufacturing facilities.

• China-based Manufacturers:

  • Qilu Pharmaceutical Co., Ltd.: A large, integrated pharmaceutical group in China with extensive API manufacturing operations. Qilu Pharmaceutical is a significant producer of Azithromycin API, with a focus on bulk production.
  • Zhejiang NHU Company Ltd.: A diversified chemical and pharmaceutical manufacturer. NHU has a substantial API business, including the production of Azithromycin, serving global pharmaceutical companies.
  • Jiangmen Meihua Pharmaceutical Co., Ltd.: A Chinese company specializing in the production of various APIs. Meihua Pharmaceutical is recognized for its Azithromycin manufacturing capacity.
  • Yantai Wanhua Chemical Group Co., Ltd.: While more broadly known for its chemical products, Wanhua Chemical has diversified into pharmaceutical intermediates and APIs, including Azithromycin.

These manufacturers operate under varying degrees of regulatory scrutiny, with facilities often inspected by bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others, depending on the target export markets.

WHAT ARE THE REGULATORY STANDARDS FOR AZITHROMYCIN API PRODUCTION?

Compliance with international regulatory standards is paramount for Azithromycin API suppliers. These standards ensure product quality, safety, and efficacy. Key regulatory frameworks and requirements include:

• Good Manufacturing Practice (GMP): All major Azithromycin API manufacturers must adhere to GMP guidelines established by regulatory authorities like the FDA (United States), EMA (Europe), WHO (World Health Organization), and national drug regulatory bodies. This includes stringent control over raw materials, manufacturing processes, quality control, and documentation.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF contains detailed information about the manufacturing process, facility, and quality control of the API. This allows regulatory bodies to review the API's manufacturing independently without revealing proprietary information to the drug product manufacturer.
• Inspections and Audits: Facilities are subject to periodic inspections by regulatory agencies (e.g., FDA, EMA) and customer audits. Successful inspection outcomes are critical for market access. For instance, FDA approval of a DMF and the associated manufacturing site is a prerequisite for using the API in products marketed in the United States.
• Pharmacopeial Standards: The Azithromycin API must meet the specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define acceptable limits for impurities, assay, and physical characteristics.
• Impurity Profiling: Manufacturers are required to identify, quantify, and control impurities in the API. This includes process-related impurities and degradation products. Regulatory agencies set strict limits for known and unknown impurities. For Azithromycin, specific impurities of concern include those related to its macrolide structure and synthesis byproducts.

Companies consistently investing in quality systems and regulatory compliance maintain a competitive advantage and broader market access. The recertification and revalidation of manufacturing sites are ongoing processes.

WHAT IS THE GLOBAL PRODUCTION CAPACITY FOR AZITHROMYCIN API?

Estimating precise global production capacity for Azithromycin API is complex due to proprietary information held by manufacturers. However, industry assessments suggest a substantial global capacity exceeding the current demand, driven by the significant role of Azithromycin as a broad-spectrum antibiotic.

• Estimated Total Global Capacity: Industry estimates place the aggregate annual production capacity for Azithromycin API in the range of 5,000 to 8,000 metric tons. This figure is a composite of capacities across major manufacturers in India, China, and other regions.
• Capacity Utilization: Actual production volumes likely operate at a utilization rate that balances market demand with cost-efficiency. Given the scale of major players, utilization rates can fluctuate based on market demand cycles and the introduction of new generic products.
• Key Capacity Contributors: Manufacturers like Divi's Laboratories, Aarti Drugs, and Laurus Labs in India, and major Chinese producers, contribute significantly to this global capacity due to their large-scale, multi-purpose API manufacturing plants.
• Backward Integration: Several leading manufacturers have backward integrated their supply chains, meaning they produce key starting materials and intermediates for Azithromycin synthesis in-house. This reduces reliance on external suppliers and can enhance cost control and supply chain stability. For example, the production of the core erythronolide A precursor is a critical step where in-house capabilities are advantageous.

The substantial capacity allows for competitive pricing and ensures adequate supply for the global pharmaceutical market, even during periods of heightened demand for antibiotics. However, disruptions in raw material sourcing or geopolitical events can still impact short-term availability.

HOW DO RAW MATERIAL COSTS AND SUPPLY CHAIN DYNAMICS AFFECT AZITHROMYCIN API PRICING?

The pricing of Azithromycin API is subject to several influencing factors, primarily driven by raw material costs, manufacturing efficiency, and global supply-demand balances.

• Key Raw Materials: The synthesis of Azithromycin involves complex organic chemistry and requires specific starting materials and reagents. Critical precursors and reagents include:
  • Erythromycin A (as a starting material for some synthetic routes) or its precursors.
  • Various sugars and carbohydrate derivatives.
  • Specialty chemicals for cyclization, methylation, and functional group modifications.
  • Solvents and catalysts used in multi-step synthesis.
• Cost Volatility: The prices of these raw materials can fluctuate based on their own market supply and demand, production costs of upstream chemical manufacturers, and global commodity prices. For instance, if the cost of a specific chiral intermediate increases due to supply constraints, it directly impacts the production cost of Azithromycin.
• Manufacturing Process Efficiency: The complexity of Azithromycin synthesis, often involving 10-15 chemical steps, means that process efficiency, yield rates, and waste management are critical cost drivers. Manufacturers with optimized processes and high yields can achieve lower per-unit production costs.
• Geographic Concentration of Suppliers: The concentration of key raw material suppliers and API manufacturers in specific regions (e.g., China and India) means that geopolitical events, trade policies, or localized environmental regulations can disrupt supply chains and influence prices.
• Scale of Production: Larger production batches generally lead to lower per-unit costs due to economies of scale. Manufacturers with high production volumes can offer more competitive pricing.
• Regulatory Compliance Costs: Investment in maintaining GMP compliance, conducting extensive quality testing, and managing regulatory submissions adds to the overall cost of production, which is factored into the final API price.
• Market Competition: The presence of multiple API manufacturers, particularly generic producers, fosters price competition. Periods of oversupply can lead to downward pressure on prices, while shortages or increased demand can drive prices up.

The typical price range for Azithromycin API on the global market can vary but often falls between $30 to $70 per kilogram, depending on the supplier, quantity, purity, and specific regulatory certifications. Fluctuations in upstream costs can cause movements within this range.

WHAT ARE THE TRENDS AND FUTURE PROSPECTS FOR AZITHROMYCIN API MANUFACTURING?

The Azithromycin API market is mature but continues to evolve, influenced by several key trends and technological advancements.

• Process Optimization and Green Chemistry: Manufacturers are increasingly focused on optimizing synthesis routes to improve yields, reduce byproducts, and minimize the use of hazardous solvents. The adoption of green chemistry principles is becoming more prominent to reduce environmental impact and operational costs. This can involve developing catalytic processes or more efficient purification techniques.
• Supply Chain Resilience: Following global supply chain disruptions, there is a growing emphasis on building more resilient supply chains. This includes diversifying raw material sources, increasing inventory levels for critical intermediates, and exploring regional manufacturing alternatives.
• Regulatory Scrutiny: Regulatory bodies worldwide continue to enhance their oversight of API manufacturing. Manufacturers must remain vigilant in maintaining the highest standards of quality and compliance to retain market access. This includes tighter controls on impurities and more frequent inspections.
• Generic Competition and Market Dynamics: As Azithromycin is off-patent, the market is primarily driven by generic manufacturers. Competition remains robust, necessitating continuous efforts in cost management and quality assurance to remain competitive. The development of new Azithromycin formulations or combination therapies could introduce new demand drivers.
• Technological Advancements: While Azithromycin synthesis is a well-established process, incremental improvements in chemical synthesis technologies, such as continuous flow manufacturing or advanced analytical techniques for impurity detection, may be adopted by leading manufacturers to enhance efficiency and quality.
• Emerging Markets: Growth in healthcare infrastructure and increased access to antibiotics in emerging economies continue to represent potential growth areas for Azithromycin API demand.

The future outlook for Azithromycin API manufacturing remains stable, underpinned by its essential role in global public health. Key success factors will involve maintaining cost-competitiveness through efficient processes, unwavering commitment to quality and regulatory compliance, and adaptable supply chain strategies.

KEY TAKEAWAYS

• Global Azithromycin API production is dominated by manufacturers in India and China, with Aarti Drugs, Divi's Laboratories, Laurus Labs, and major Chinese chemical and pharmaceutical companies being key players.
• Strict adherence to GMP, pharmacopeial standards, and successful regulatory inspections are critical for market access and supplier credibility.
• Global Azithromycin API production capacity is estimated to be between 5,000 to 8,000 metric tons annually, significantly exceeding current demand.
• Azithromycin API pricing is influenced by raw material costs, manufacturing efficiency, economies of scale, and competitive market dynamics, with prices typically ranging from $30 to $70 per kilogram.
• Future trends in Azithromycin API manufacturing include process optimization, green chemistry adoption, enhanced supply chain resilience, and ongoing rigorous regulatory oversight.

FAQS

1. Are there any patented manufacturing processes for Azithromycin that limit supply? Azithromycin itself is a well-established generic drug, and its primary patents have long expired. While specific novel synthesis routes or purification methods might be patented by individual manufacturers, the core processes for producing Azithromycin API are generally available for generic use.
2. What are the implications of FDA warning letters for an Azithromycin API supplier? An FDA warning letter signifies significant compliance issues at a manufacturing facility. For an Azithromycin API supplier, this can lead to import alerts, a halt in shipments to the U.S., and damage to their reputation, potentially impacting their ability to supply customers globally and necessitating substantial corrective actions.
3. How does the cost of Erythromycin A, a potential precursor, influence Azithromycin API prices? If manufacturers utilize Erythromycin A as a starting material, fluctuations in its price directly impact Azithromycin API production costs. Supply constraints or price increases for Erythromycin A will typically translate to higher Azithromycin API prices, assuming other factors remain constant.
4. What is the typical lead time for securing a large order of Azithromycin API from a major supplier? Lead times for large Azithromycin API orders can range from 4 to 12 weeks. This depends on the supplier's current production schedule, existing inventory, the scale of the order, and the complexity of logistics and quality documentation required for shipment to the destination country.
5. Are there significant environmental concerns associated with Azithromycin API manufacturing? Like many complex organic syntheses, Azithromycin API manufacturing can involve the use of solvents and generate chemical waste. Manufacturers are increasingly adopting greener synthesis pathways and investing in waste treatment facilities to mitigate environmental impact, in line with global environmental regulations and corporate responsibility initiatives.

CITATIONS

[1] Aarti Drugs Ltd. (n.d.). Products: API. Retrieved from https://www.aartidrugs.com/api [2] Divi's Laboratories Ltd. (n.d.). Products: Active Pharmaceutical Ingredients. Retrieved from https://www.divislabs.com/products/active-pharmaceutical-ingredients/ [3] Laurus Labs Ltd. (n.d.). APIs. Retrieved from https://www.lauruslabs.com/apis/ [4] Natco Pharma Ltd. (n.d.). API Products. Retrieved from https://www.natcopharma.co.in/api-products [5] Granules India Ltd. (n.d.). API Portfolio. Retrieved from https://www.granulesindia.com/apis [6] Qilu Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.qilu-pharma.com/en/products/ [7] Zhejiang NHU Company Ltd. (n.d.). Pharmaceuticals. Retrieved from https://www.nuhe.cn/en/Products/Pharmaceuticals.html [8] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-gmp/good-manufacturing-practice-gmp [9] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/manufacturing-medicines [10] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/